Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Simeprevir is safe and effective with interferon/ribavirin for hepatitis C patients with cirrhosis

The hepatitis C protease inhibitor simeprevir (formerly TMC435) was generally safe and well tolerated in people with advanced liver fibrosis or cirrhosis and improved sustained response rates

Published
19 November 2012
By
Liz Highleyman
New second generation combination therapy for HCV - first or best in the market

This article is Part 1 in a series about Hepatitis C intended to provide an update and fundamental analysis of the companies that are actively pursuing the development of an all oral therapy for HCV.

Published
19 November 2012
From
Seeking Alpha
Copy of New second generation combination therapy for HCV - first or best in the market

This article is Part 1 in a series about Hepatitis C intended to provide an update and fundamental analysis of the companies that are actively pursuing the development of an all oral therapy for HCV.

Published
19 November 2012
From
Seeking Alpha
Sofosbuvir demonstrates high response rate in interferon-free combination with ribavirin and GS-5885

The hepatitis C polymerase inhibitor sofosbuvir produced high rates of sustained virological response in genotype 1 patients when combined with ribavirin and the HCV NS5A inhibitor GS-5885,

Published
15 November 2012
By
Liz Highleyman
Gilead may move ahead of rivals with hepatitis C results

Gilead Sciences Inc. (GILD) may have an edge on rivals developing new hepatitis C drugs for a potential $20 billion market after a study showed its experimental drugs cleared the liver disease virus in 100 percent of patients.

Published
15 November 2012
From
Bloomberg Businessweek
Copy of Gilead may move ahead of rivals with hepatitis C results

Gilead Sciences Inc. (GILD) may have an edge on rivals developing new hepatitis C drugs for a potential $20 billion market after a study showed its experimental drugs cleared the liver disease virus in 100 percent of patients.

Published
15 November 2012
From
Bloomberg Businessweek
Abbott Announces Phase 3 Interferon-free Hepatitis C Regimens to be Studied in Broad Patient Populations

The phase 3 clinical trials are designed to evaluate safety and efficacy of a 12-week regimen of three direct acting antivirals (DAA), with and without ribavirin, for the treatment of HCV in genotype 1 (GT1) non-cirrhotic, treatment-naïve and treatment-experienced patients. An additional phase 3 trial will study triple-DAAs, with ribavirin, in patients with cirrhosis for 12 or 24 weeks.

Published
14 November 2012
From
Abbott press release
94% response rate to HCV treatment without ribavirin or interferon in harder-to-treat

Twelve weeks of treatment with a three-drug combination of new directly acting antivirals that contained neither pegylated interferon nor ribavirin led to a sustained virologic response 12

Published
13 November 2012
By
Keith Alcorn
Reducing ribavirin and adding EPO are both good anaemia management strategies for people taking boceprevir

Chronic hepatitis C patients treated with boceprevir (Victrelis) plus pegylated interferon and ribavirin can effectively manage drug-induced anaemia by either ribavirin dose reduction or addition of erythropoietin

Published
13 November 2012
By
Liz Highleyman
Hep C Competitors Cede Space To Gilead And Bristol-Myers And Turn To Niche Uses

The analyst community might have already written the epitaph for Vertex Pharmaceuticals’ (VRTX) Incivek and Merck & Co’s (MRK) Victrelis, but the search for growth for the two hepatitis C treatments continues apace. The AASLD Liver Meeting became an opportunity for the two companies to showcase potential new uses in hard-to-treat populations.

Published
13 November 2012
From
Seeking Alpha

Filter by country